Compare IPCA Labs with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SHASUN PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SHASUN PHARMA IPCA LABS/
SHASUN PHARMA
 
P/E (TTM) x 22.9 123.9 18.5% View Chart
P/BV x 4.4 8.5 52.1% View Chart
Dividend Yield % 0.1 0.2 45.3%  

Financials

 IPCA LABS   SHASUN PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
SHASUN PHARMA
Mar-14
IPCA LABS/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs69594 738.2%   
Low Rs40046 877.2%   
Sales per share (Unadj.) Rs260.2214.2 121.5%  
Earnings per share (Unadj.) Rs19.05.3 355.5%  
Cash flow per share (Unadj.) Rs33.115.8 208.9%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %0.21.4 12.8%  
Book value per share (Unadj.) Rs213.053.3 399.4%  
Shares outstanding (eoy) m126.2056.62 222.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.10.3 645.0%   
Avg P/E ratio x28.913.1 220.4%  
P/CF ratio (eoy) x16.64.4 375.0%  
Price / Book Value ratio x2.61.3 196.2%  
Dividend payout %5.318.7 28.1%   
Avg Mkt Cap Rs m69,1203,958 1,746.4%   
No. of employees `00013.3NA-   
Total wages/salary Rs m7,3592,164 340.1%   
Avg. sales/employee Rs Th2,477.4NM-  
Avg. wages/employee Rs Th555.2NM-  
Avg. net profit/employee Rs Th180.6NM-  
INCOME DATA
Net Sales Rs m32,83612,127 270.8%  
Other income Rs m418229 182.3%   
Total revenues Rs m33,25412,356 269.1%   
Gross profit Rs m4,5051,009 446.4%  
Depreciation Rs m1,777594 299.4%   
Interest Rs m240415 57.9%   
Profit before tax Rs m2,905230 1,264.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m511-73 -702.8%   
Profit after tax Rs m2,394302 792.5%  
Gross profit margin %13.78.3 164.9%  
Effective tax rate %17.6-31.7 -55.6%   
Net profit margin %7.32.5 292.7%  
BALANCE SHEET DATA
Current assets Rs m19,4556,884 282.6%   
Current liabilities Rs m10,0768,456 119.2%   
Net working cap to sales %28.6-13.0 -220.4%  
Current ratio x1.90.8 237.2%  
Inventory Days Days9862 158.8%  
Debtors Days Days67108 62.2%  
Net fixed assets Rs m20,2604,970 407.6%   
Share capital Rs m252113 222.8%   
"Free" reserves Rs m26,6332,875 926.4%   
Net worth Rs m26,8863,020 890.2%   
Long term debt Rs m2,3401,817 128.8%   
Total assets Rs m41,17313,347 308.5%  
Interest coverage x13.11.6 843.0%   
Debt to equity ratio x0.10.6 14.5%  
Sales to assets ratio x0.80.9 87.8%   
Return on assets %6.45.4 119.1%  
Return on equity %8.910.0 89.0%  
Return on capital %10.813.3 80.8%  
Exports to sales %47.646.4 102.8%   
Imports to sales %14.914.2 104.4%   
Exports (fob) Rs m15,6425,622 278.3%   
Imports (cif) Rs m4,8841,728 282.7%   
Fx inflow Rs m15,6425,843 267.7%   
Fx outflow Rs m4,8842,173 224.7%   
Net fx Rs m10,7593,669 293.2%   
CASH FLOW
From Operations Rs m3,411398 858.0%  
From Investments Rs m-1,354-1,635 82.8%  
From Financial Activity Rs m-1,3041,309 -99.7%  
Net Cashflow Rs m75371 1,057.9%  

Share Holding

Indian Promoters % 45.9 39.2 117.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 3.6 316.7%  
FIIs % 25.3 17.6 143.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 39.6 43.9%  
Shareholders   36,892 20,750 177.8%  
Pledged promoter(s) holding % 2.1 12.3 17.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  ABBOTT INDIA  PLETHICO PHARMA  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 16, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS